Transcription Factor CUTL1 Is a Negative Regulator of Drug Resistance in Gastric Cancer*

Background: Transcription factors play crucial roles in drug resistance in cancer. Results: CUTL1 activity decreased in gastric cancer with a drug resistance phenotype. Modulation of CUTL1 expression led to changes of cancer cell responses to chemotherapy. Conclusion: CUTL1 modulates multidrug resistance in gastric cancer. Significance: CUTL1 is a potential target for improving chemotherapeutic efficacy for gastric cancer. Gastric cancer is one of the leading causes of malignancy-related mortality worldwide, and drug resistance hampered the clinical efficacy of chemotherapy. To better understand the molecular mechanism causing drug resistance, we previously established an isogenic pair of doxorubicin-sensitive and -resistant gastric cancer cell lines, SGC7901 and SGC7901/ADR cells. Here, we investigated how modulation of CUTL1 activity affects the response of gastric cancer to frequently used chemotherapeutic agents. In this study, we demonstrated that CUTL1 transcription activity was significantly reduced in doxorubicin-resistant cells. Furthermore, decreased CUTL1 expression was strongly associated with intrinsic drug resistance in human gastric cancer tissues and could be used as a poor prognosis biomarker. Both gain-of-function (by overexpression of active CUTL1) and loss-of-function (by CUTL1-specific shRNA knockdown) studies showed that increased CUTL1 activity significantly enhanced cell sensitivity to drugs and led to increased apoptosis, whereas decreased CUTL1 expression dramatically reduced cell sensitivity to drugs and thus fewer apoptoses. Importantly, modulation of CUTL1 activity resulted in altered sensitivity to multiple drugs. In vivo mouse studies indicated that overexpression of active CUTL1 significantly resulted in increased cancer tissue response to chemotherapy and therefore inhibited growth, whereas knockdown of CUTL1 conferred resistance to chemotherapy. Taken together, our results strongly indicate that CUTL1 activity is inversely associated with drug resistance and thus is an attractive therapeutic target to modulate multidrug resistance in gastric cancer.

[1]  G. Salvesen,et al.  Carboxyl-terminal Proteolytic Processing of CUX1 by a Caspase Enables Transcriptional Activation in Proliferating Cells* , 2007, Journal of Biological Chemistry.

[2]  Y. Kodera,et al.  In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues , 2006, International Journal of Clinical Oncology.

[3]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[4]  R. Scheuermann,et al.  Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. , 2001, Blood.

[5]  C. D'Arrigo,et al.  CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness , 2005 .

[6]  W. V. Berghe,et al.  Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols , 2010, Molecular Cancer.

[7]  Laurent Sansregret,et al.  The multiple roles of CUX1: insights from mouse models and cell-based assays. , 2008, Gene.

[8]  Zhiguo Liu,et al.  Prediction of doxorubicin sensitivity in gastric cancers based on a set of novel markers. , 2008, Oncology reports.

[9]  Liang Zhang,et al.  Novel high-throughput profiling of human transcription factors and its use for systematic pathway mapping. , 2008, Journal of proteome research.

[10]  Julian Downward,et al.  CUTL1 Is Phosphorylated by Protein Kinase A, Modulating Its Effects on Cell Proliferation and Motility* , 2006, Journal of Biological Chemistry.

[11]  Qiang Yu,et al.  Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. , 2002, Cancer letters.

[12]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[13]  F. Robert,et al.  p110 CUX1 Cooperates with E2F Transcription Factors in the Transcriptional Activation of Cell Cycle-Regulated Genes , 2008, Molecular and Cellular Biology.

[14]  D. Fan,et al.  Overexpression and significance of prion protein in gastric cancer and multidrug‐resistant gastric carcinoma cell line SGC7901/ADR , 2005, International journal of cancer.

[15]  D. Fan,et al.  MiR-218 Inhibits Invasion and Metastasis of Gastric Cancer by Targeting the Robo1 Receptor , 2010, PLoS genetics.

[16]  B. Goulet,et al.  CDP/Cux stimulates transcription from the DNA polymerase alpha gene promoter. , 2003, Molecular and cellular biology.

[17]  Tingting Li,et al.  Identification of GAS1 as an Epirubicin Resistance-related Gene in Human Gastric Cancer Cells with a Partially Randomized Small Interfering RNA Library* , 2009, The Journal of Biological Chemistry.

[18]  H. Izumi,et al.  Transcription factors and drug resistance. , 2005, European journal of cancer.

[19]  D. Fan,et al.  TRF2 promotes multidrug resistance in gastric cancer cells , 2006, Cancer biology & therapy.

[20]  B. Goulet,et al.  CDP/Cux Stimulates Transcription from the DNA Polymerase α Gene Promoter , 2003, Molecular and Cellular Biology.

[21]  T. Gress,et al.  Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancer. , 2010, Neoplasia.

[22]  W. Shao,et al.  Parallel profiling of active transcription factors using an oligonucleotide array-based transcription factor assay (OATFA). , 2005, Journal of proteome research.

[23]  Shuang-yin Han,et al.  ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[24]  B. Sikic,et al.  CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells , 2004 .

[25]  Xiaohua Li,et al.  p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells. , 2007, Neoplasia.

[26]  E. Cummins,et al.  c-Jun NH2-Terminal Kinase Activation Contributes to Hypoxia-Inducible Factor 1α–Dependent P-Glycoprotein Expression in Hypoxia , 2004, Cancer Research.

[27]  Xiaohua Li,et al.  A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[28]  D. Fan,et al.  Inhibition of PI3K/Akt partially leads to the inhibition of PrPC‐induced drug resistance in gastric cancer cells , 2009, The FEBS journal.

[29]  Y. Doki,et al.  Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. , 2009, Anticancer research.

[30]  J. Ajani,et al.  Gastric cancer--an enigmatic and heterogeneous disease. , 2010, JAMA.

[31]  A. Nepveu,et al.  Biochemical characterization of the mammalian Cux2 protein. , 2005, Gene.